Edition:
United Kingdom

Chugai Pharmaceutical Co Ltd (4519.T)

4519.T on Tokyo Stock Exchange

5,600JPY
17 Nov 2017
Change (% chg)

¥-110 (-1.93%)
Prev Close
¥5,710
Open
¥5,780
Day's High
¥5,790
Day's Low
¥5,570
Volume
1,487,900
Avg. Vol
860,325
52-wk High
¥5,790
52-wk Low
¥3,010

Chart for

About

CHUGAI PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company. The Domestic segment is engaged in the sale of pharmaceutical products manufactured by the Company through its nationwide appointed stores. This segment is also involved in the research, development, transportation and storage of pharmaceutical products, as... (more)

Overall

Beta: 0.64
Market Cap(Mil.): ¥2,650,113.00
Shares Outstanding(Mil.): 559.69
Dividend: 29.00
Yield (%): 1.16

Financials

  Industry Sector
P/E (TTM): -- 31.19 16.41
EPS (TTM): -- -- --
ROI: -- 14.93 10.66
ROE: -- 16.20 14.26

BRIEF-R&I affirms Chugai Pharmaceutical's rating at "AA-" and says stable outlook -R&I

* Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA-" -R&I

16 Nov 2017

Roche's Chugai transfers rights of 13 Long-Term Listed Products to Taiyo

ZURICH, Nov 14 Chugai Pharmaceuticals, a Japan-based Roche subsidiary, said on Tuesday it has agreed to transfer the marketing and manufacturing right of 13 long-term listed products to Taiyo Holdings' Taiyo Pharma.

14 Nov 2017

BRIEF-Marketing and manufacturing right transfer of 13 long-term listed products from Chugai Pharmaceutical to Taiyo Pharma

* Says it and TAIYO HOLDINGS CO LTD announced today that they have entered into an agreement, under which the co and F. Hoffmann-La Roche, Ltd. will transfer the marketing authorizations, including marketing and manufacturing rights, of 13 long-term listed products manufactured and marketed in Japan by Chugai to TAIYO Pharma Co., Ltd., a wholly owned subsidiary of Taiyo Holdings

14 Nov 2017

BRIEF-Chugai Pharma considering selling production rights of some medications to Taiyo - Nikkei

* Chugai Pharma considering selling production, sales rights of some 15 medications with expired patents to Taiyo Holdings for about 20 billion yen - Nikkei Source text : (http://s.nikkei.com/2iRwewI) Further company coverage:

13 Nov 2017

BRIEF-Chugai Pharmaceutical aims to increase core oper profit to more than 100 bln Yen in year ending Dec. 2019 - Nikkei

* Chugai Pharmaceutical Co Ltd aims to increase its core operating profit to more than 100 billion yen ($920 million) in the year ending December 2019 - Nikkei Source text (http://s.nikkei.com/2x6fubs) Further company coverage:

21 Aug 2017

Earnings vs. Estimates